Since HDACs, tumor-promoting enzymes causing deacetylation of acetyl-lysine (KAc) residues on their substrates (histones and non-histone proteins), have emerged as candidates for epigenetic effects, we evaluated how JAK/HDACi, regorafenib, and their combination modulate acetylation of histones. The gene discussed is H2BC12L; the disease is neoplasm.